U.S. Nasal Spray Market, by Type (Prescription based(Branded, Generic), Over-The-Counter(Branded, Generic)), by Product Type ((Prescription based [Steroid Sprays{ Beclomethasone, Azelastine Hydrochloride And Fluticasone Propionate, Flunisolide, Mometasone

U.S. Nasal Spray Market, by Type (Prescription based(Branded, Generic), Over-The-Counter(Branded, Generic)), by Product Type ((Prescription based [Steroid Sprays{ Beclomethasone, Azelastine Hydrochloride And Fluticasone Propionate, Flunisolide, Mometasone Furoate , Fluticasone, Triamcinolone Acetonide , Budesonide, Others }], [Antihistamine Sprays {Azelastine, Olopatadine Hydrochloride}], [Decongestant Sprays], [Others {Ipratropium Bromide, Naloxone, Others}]) (Over-the-Counter [Steroid Sprays {Fluticasone, Triamcinolone, Budesonide}] [Decongestant Sprays{Oxymetazoline, Phenylephrine, Xylometazoline}], [Saline Nasal Spray], Others)) by Indication (Allergic Rhinitis, Nasal Allergies, Nasal Congestion, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

A nasal spray is a medication that is sprayed into the nostril in a fine mist from a container. Nasal sprays are used locally to treat problems such as nasal congestion and allergic rhinitis. In some cases, the nasal delivery route is used for systemic therapy since it is a more pleasant alternative to injections or pills. When ingested directly through the nose, substances can be absorbed very quickly.

Market Dynamics

Increase in number of acquisitions between market players is expected to boost the U.S. nasal spray market growth over the forecast period. For instance, in October 2018, Emergent BioSolutions, a U.S. based biopharmaceutical company announced acquisition of Adapt Pharma, a pharmaceutical company, developing therapeutic treatments for patients with special medical conditions and its flagship product NARCAN (naloxone HCl) Nasal Spray. NARCAN (naloxone HCl) is first and only intranasal form of naloxone approved by the U.S. Food and Drug Administration (FDA) and Health Canada, for the emergency treatment of known or suspected opioid overdose.

Increasing number of product launches by market players are expected to bolster growth of the U.S. nasal spray market. For instance in December 2021, Sandoz, a global company in generic and biosimilar medicines, announced the launch of its authorized generic Narcan (naloxone hydrochloride) Nasal Spray 4mg in the U.S. indicated to reverse opioid overdose. People in the U.S. can buy it from retail pharmacies and other facilities, like hospitals.

Market players are engaged in nasal spray launching in U.S. are expected to drive growth of market over the forecast period. For instance, on August 31 2022, Glenmark Pharma, a multinational pharmaceutical company, launched Ryaltris nasal spray for allergic rhintis in the U.S. It will be distributed by Hikma Pharmaceuticals, a British Pharmaceutical company in the US. Ryaltris is the only-approved fixed-dose combination therapy for seasonal allergic rhinitis in the US market.

Key features of the study:

• This report provides an in-depth analysis of U.S. nasal spray market, market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year.
• It elucidates potential revenue opportunities across different segments and explains an attractive investment proposition matrix for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the U.S. nasal spray market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include GlaxoSmithKline plc, Sanofi S.A., Bayer AG, Merck & Co., Inc., Novartis AG, Johnson & Johnson Services, Inc., Pfizer Inc., Procter & Gamble, AstraZeneca Plc., NeilMed Pharmaceuticals Inc., Church & Dwight Co., Inc., and Neurelis, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make an informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics.
• The U.S. nasal spray market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the U.S. nasal spray market.

Detailed Segmentation:

• U.S. Nasal Spray Market ,By Type:
• Prescription Based
• Branded
• Generic
• Over-the-Counter
• Branded
• Generic
• U.S. Nasal Spray Market , By Product Type:
• Prescription Based
• Steroid Sprays
• Beclomethasone
• Azelastine Hydrochloride And Fluticasone Propionate
• Flunisolide
• Mometasone Furoate
• Fluticasone
• Triamcinolone Acetonide
• Budesonide
• Others
• Antihistamine Sprays
• Azelastine
• Olopatadine Hydrochloride
• Decongestant Sprays (Oxymetazoline)
• Saline Nasal Sprays
• Others
• Ipratropium Bromide
• Naloxone
• Over-the-Counter
• Steroid Sprays
• Fluticasone
• Triamcinolone
• Budesonide
• Decongestant Sprays
• Oxymetazoline
• Phenylephrine
• Xylometazoline
• Saline Nasal Sprays
• Others (Cromoglicic acid (NasalCrom)
• U.S. Nasal Spray Market , By Indication:
• Allergic Rhinitis
• Nasal Allergies
• Nasal Congestion
• Others
• U.S. Nasal Spray Market , By Distribution Channel:
• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Company Profiles
• GlaxoSmithKline plc *
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
• Sanofi S.A.
• Bayer AG
• Merck & Co., Inc.
• Novartis AG
• Johnson & Johnson Services, Inc.
• Pfizer Inc.
• Procter & Gamble
• AstraZeneca Plc.
• NeilMed Pharmaceuticals Inc.
• Church & Dwight Co., Inc.
• Neurelis, Inc.

“*” marked represents similar segmentation in other categories in the respective section.